Daito PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Daito PharmaceuticalLtd's earnings have been declining at an average annual rate of -7.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 0.03% per year. Daito PharmaceuticalLtd's return on equity is 4.6%, and it has net margins of 5.6%.
Key information
-7.2%
Earnings growth rate
-9.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 0.03% |
| Return on equity | 4.6% |
| Net Margin | 5.6% |
| Last Earnings Update | 30 Nov 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Daito PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Nov 24 | 47,369 | 2,651 | 3,438 | 2,349 |
| 31 Aug 24 | 47,395 | 3,230 | 3,438 | 2,349 |
| 31 May 24 | 46,895 | 3,295 | 3,431 | 2,349 |
| 29 Feb 24 | 45,193 | 3,279 | 3,412 | 1,865 |
| 30 Nov 23 | 45,844 | 3,390 | 3,388 | 1,865 |
| 31 Aug 23 | 45,238 | 3,337 | 3,196 | 1,865 |
| 31 May 23 | 45,101 | 3,600 | 3,078 | 1,865 |
| 28 Feb 23 | 44,451 | 3,350 | 3,372 | 1,749 |
| 30 Nov 22 | 44,368 | 3,653 | 3,399 | 1,749 |
| 31 Aug 22 | 43,759 | 3,789 | 3,349 | 1,749 |
| 31 May 22 | 43,464 | 4,668 | 2,990 | 1,749 |
| 28 Feb 22 | 44,462 | 4,525 | 2,658 | 2,032 |
| 30 Nov 21 | 45,142 | 4,600 | 2,561 | 2,032 |
| 31 Aug 21 | 46,757 | 4,750 | 2,436 | 2,032 |
| 31 May 21 | 48,714 | 4,246 | 2,712 | 2,032 |
| 28 Feb 21 | 48,454 | 4,402 | 3,175 | 1,400 |
| 30 Nov 20 | 47,773 | 4,365 | 3,013 | 1,400 |
| 31 Aug 20 | 47,036 | 4,345 | 2,926 | 1,400 |
| 31 May 20 | 44,991 | 3,944 | 2,609 | 1,400 |
| 29 Feb 20 | 45,105 | 4,204 | 2,366 | 1,608 |
| 30 Nov 19 | 44,242 | 3,842 | 2,251 | 1,608 |
| 31 Aug 19 | 43,053 | 3,654 | 2,283 | 1,608 |
| 31 May 19 | 41,134 | 3,513 | 2,394 | 1,608 |
| 28 Feb 19 | 40,640 | 3,291 | 2,300 | 1,522 |
| 30 Nov 18 | 39,566 | 3,127 | 2,405 | 1,522 |
| 31 Aug 18 | 39,933 | 3,147 | 2,246 | 1,522 |
| 31 May 18 | 39,875 | 3,041 | 2,301 | 1,522 |
| 28 Feb 18 | 39,701 | 2,913 | 2,554 | 1,266 |
| 30 Nov 17 | 39,219 | 2,820 | 2,414 | 1,266 |
| 31 Aug 17 | 38,554 | 2,658 | 2,542 | 1,266 |
| 31 May 17 | 37,984 | 2,656 | 2,394 | 1,266 |
| 28 Feb 17 | 37,283 | 2,698 | 2,523 | 1,174 |
| 30 Nov 16 | 37,270 | 2,722 | 2,438 | 1,174 |
| 31 Aug 16 | 36,747 | 2,559 | 2,282 | 1,174 |
| 31 May 16 | 36,370 | 2,566 | 2,348 | 1,174 |
| 29 Feb 16 | 36,416 | 2,639 | 2,107 | 1,182 |
| 30 Nov 15 | 35,691 | 2,403 | 2,358 | 1,182 |
| 31 Aug 15 | 35,370 | 2,468 | 2,353 | 1,182 |
| 31 May 15 | 34,058 | 2,246 | 2,243 | 1,182 |
| 28 Feb 15 | 33,765 | 2,080 | 2,531 | 890 |
| 30 Nov 14 | 32,528 | 2,010 | 2,168 | 890 |
| 31 Aug 14 | 31,560 | 1,864 | 2,033 | 890 |
| 31 May 14 | 31,196 | 1,811 | 2,029 | 890 |
| 28 Feb 14 | 29,876 | 1,910 | 1,751 | 1,113 |
Quality Earnings: DAIT.F has a large one-off gain of ¥704.0M impacting its last 12 months of financial results to 30th November, 2024.
Growing Profit Margin: DAIT.F's current net profit margins (5.6%) are lower than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DAIT.F's earnings have declined by 7.2% per year over the past 5 years.
Accelerating Growth: DAIT.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DAIT.F had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (42%).
Return on Equity
High ROE: DAIT.F's Return on Equity (4.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 08:56 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/11/30 |
| Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daito Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yukichi Okabe | Okasan Securities Co. Ltd. |
| Takashi Akahane | Tokai Tokyo Intelligence Laboratory Co., Ltd. |
| Masao Yoshida | Tokai Tokyo Intelligence Laboratory Co., Ltd. |